This is a correction to: Emely L Verweyen, Grant S Schulert, Interfering with interferons: targeting the JAK-STAT pathway in complications of systemic juvenile idiopathic arthritis (SJIA), Rheumatology, Volume 61, Issue 3, March 2022, Pages 926–935, https://doi.org/10.1093/rheumatology/keab673
In the originally published version of this manuscript, the second paragraph of the section “Therapeutic approaches targeting IFNs in SJIA, SJIA-MAS and SJIA-LD” referred to ongoing “controlled trials” for Emapalumab. This should have been referred to as an “open-label clinical trial”.
This error has been corrected online.